- Email: [email protected]
High PAI levels and reduced fibrinolytic activity in obese subjects: markers of a prethrombotic state?
20
FIBRINOLYSIS
47 High PAI levels and reduced fibrinolytic
activity in obese subjects: markers of a prethrombotic state? CRAVERIA, TORNAGHI G, RANIEIUR PAGANARDI I, PASSARETTI B, GL4 VARDI L, *hURELLI F, *MORONI GA Div. Medicina Generale II e *Unita Operativa i”kansfusionaleOspedale San Paolo, V Di Rudini Milano, Italy Obesity is now considered an atherogenic risk factor. Previous studies have shown variations in fibrinolytic pattern of obese subjects as reduced plasma fibrinolytic activity, increased PAI levels and high factor VII coagulant activity. Aim of our study was to investigate whether this fibrinolytic impairment was related to overweight itself or to associated cardiovascular risk factors. Population in study was com-
48 Factor VII as a marker of a thrombophlllc state in obesity CRA VERIA, TORNAGHI G, RANIERl R, PAGANARDI L, BOLLA TI p, CIElTO S, *CORl p, *MORONI GA Div. Medicina II e *U. 0. l?ansfusionale Ospedale San Paolo, Milano, Italy Northwick Park Heart Study showed increased factor VII activity is associated to cardiovascular diseases. Obesity may be considered an independent risk factor for atherosclerosis. Aim of our study was to investigate the behavior of factor VII in a group of obese subjects and to relate it to the degree of the overweight and to other lipidic and hemocoagulative parameters. Population in study was composed by 62 obese people (21 males and 41 females), aged 25 to 50, BMI = 35.4425.44, not affected by diabetes mellitus, hyperlipidaemia, hypertension, not smoking and not taking any drug and, as controls, by 32 non obese subjects. We deter-
49 Acquired heparin cofactor II deficiency in renal allograft recipients is not a risk factor for the development of thrombosis TOULON P, “MOULONGUET-DOLERIS L, COSTA JM, ALACHM Laboratoire d’Hemostase and *Clinique Nephrologique, Hopital Broussais, Paris, France Heparin Cofactor II (HC II) is an inhibitor of thrombin in human plasma, which displays great similarities with antithrombin III (AT III). Case of recurrent thromboembolism have been recently reported in patients with hereditary HC II deficiency. Since thromboembolism constitutes an important post-operative complication after renal transplantation, the plasma levels of HC II as well as AT III levels were measured in 118 healthy renal allograft recipients @AR), and compared to the values obtained in 120 age and sex matched healthy blood donors. HC II was found significantly
posed by 64 obese people and 32 non obese subjects, not affected by cardiovascular risk factors other than obesity. We determined plasma fibrinolytic activity (by fibrin plate assay by Astrup) and PAI activity (by a chromogenic assay). Our data show decreased fibrinolytic activity (8.9&2.0 mm vs. 11.2k2.6 mm, ~~0.01) and increased PAI levels (X4+5.9 AU vs. 14.324.2 AU, pcO.01) in obese people. We found a direct relation between BMI and PAI (r=0.353) and an inverse one between BMI and plasma fibrinolytic activity (r=-0.436). So the impairment of the fibrinolytic system in obesity is related to overweight itself and could be responsible for the increased cardiovascular risk.
mined factor VII coagulant activity by a coagulometric method, fibrinogen by a kinetic test, total cholesterol, triglycerides. Our data show increased factor VII activity in obese people (112.21*27.90% vs. 97.37&19.95%, p=O.Ol). There was s strong correlation between factor VII and fibrinogen (r=0.471), and between factor VII and cholesterol (r=0.472), a lighter one between factor VII and BMI (r=0.280) and triglycerides (r=0.288). We conclude that high levels of factor VII coagulant may be in part responsible for the thrombophilic state in obesity.
(p
FIBRINOLYSIS
47 High PAI levels and reduced fibrinolytic
activity in obese subjects: markers of a prethrombotic state? CRAVERIA, TORNAGHI G, RANIEIUR PAGANARDI I, PASSARETTI B, GL4 VARDI L, *hURELLI F, *MORONI GA Div. Medicina Generale II e *Unita Operativa i”kansfusionaleOspedale San Paolo, V Di Rudini Milano, Italy Obesity is now considered an atherogenic risk factor. Previous studies have shown variations in fibrinolytic pattern of obese subjects as reduced plasma fibrinolytic activity, increased PAI levels and high factor VII coagulant activity. Aim of our study was to investigate whether this fibrinolytic impairment was related to overweight itself or to associated cardiovascular risk factors. Population in study was com-
48 Factor VII as a marker of a thrombophlllc state in obesity CRA VERIA, TORNAGHI G, RANIERl R, PAGANARDI L, BOLLA TI p, CIElTO S, *CORl p, *MORONI GA Div. Medicina II e *U. 0. l?ansfusionale Ospedale San Paolo, Milano, Italy Northwick Park Heart Study showed increased factor VII activity is associated to cardiovascular diseases. Obesity may be considered an independent risk factor for atherosclerosis. Aim of our study was to investigate the behavior of factor VII in a group of obese subjects and to relate it to the degree of the overweight and to other lipidic and hemocoagulative parameters. Population in study was composed by 62 obese people (21 males and 41 females), aged 25 to 50, BMI = 35.4425.44, not affected by diabetes mellitus, hyperlipidaemia, hypertension, not smoking and not taking any drug and, as controls, by 32 non obese subjects. We deter-
49 Acquired heparin cofactor II deficiency in renal allograft recipients is not a risk factor for the development of thrombosis TOULON P, “MOULONGUET-DOLERIS L, COSTA JM, ALACHM Laboratoire d’Hemostase and *Clinique Nephrologique, Hopital Broussais, Paris, France Heparin Cofactor II (HC II) is an inhibitor of thrombin in human plasma, which displays great similarities with antithrombin III (AT III). Case of recurrent thromboembolism have been recently reported in patients with hereditary HC II deficiency. Since thromboembolism constitutes an important post-operative complication after renal transplantation, the plasma levels of HC II as well as AT III levels were measured in 118 healthy renal allograft recipients @AR), and compared to the values obtained in 120 age and sex matched healthy blood donors. HC II was found significantly
posed by 64 obese people and 32 non obese subjects, not affected by cardiovascular risk factors other than obesity. We determined plasma fibrinolytic activity (by fibrin plate assay by Astrup) and PAI activity (by a chromogenic assay). Our data show decreased fibrinolytic activity (8.9&2.0 mm vs. 11.2k2.6 mm, ~~0.01) and increased PAI levels (X4+5.9 AU vs. 14.324.2 AU, pcO.01) in obese people. We found a direct relation between BMI and PAI (r=0.353) and an inverse one between BMI and plasma fibrinolytic activity (r=-0.436). So the impairment of the fibrinolytic system in obesity is related to overweight itself and could be responsible for the increased cardiovascular risk.
mined factor VII coagulant activity by a coagulometric method, fibrinogen by a kinetic test, total cholesterol, triglycerides. Our data show increased factor VII activity in obese people (112.21*27.90% vs. 97.37&19.95%, p=O.Ol). There was s strong correlation between factor VII and fibrinogen (r=0.471), and between factor VII and cholesterol (r=0.472), a lighter one between factor VII and BMI (r=0.280) and triglycerides (r=0.288). We conclude that high levels of factor VII coagulant may be in part responsible for the thrombophilic state in obesity.
(p